The 2009 consensus statement on medical management of hyperglycemia in type 2 diabetes does not reflect official position of the ADA but rather the expert opinion of the authors of the paper.
Recently, additional information regarding the cardiovascular safety of rosiglitazone was reported, with some analyses suggesting a possible increase in risk and others supporting the drug’s safety. This information as well as past reports of a potential increase in the risk of CVD is being reviewed by the FDA. The Association’s staff and volunteer leadership are also reviewing the information in the public domain and await further information from the FDA. Until further information is provided, patients and health care professionals should continue to recognize that multiple classes of drugs, often with more than one agent per class, are available to maintain glucose control in type 2 diabetes.
The decision whether or not to use any medication must remain that of the treating physician in direct discussion with their patients. As additional information become available, the Association will provide detailed updates for both health care professionals and patients with diabetes. Patients should continue taking all currently prescribed medications unless otherwise informed by their health care team.
The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.